声明：市场有风险，投资需谨慎。本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验， 因此本文内容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联 系biz@staff.sina.com.cn。 责任编辑：小浪快报 2026年2月3日，ST未名（维权）（sz002581）触及涨停，涨停价7.55元，涨幅5.01%，总市值49.81亿 元，流通市值30.26亿元，截止发稿，总成交额2921.48万元。 根据喜娜AI异动分析，ST未名涨停原因可能如下，创新药研发+经营改善+产业链完善： 1、公司创新 药 SMR001滴眼液获 III 期临床批件，该药物针对 180 亿规模的干眼症市场，具有修复角膜神经的独特 技术优势。创新药研发的进展是刺激股价涨停的重要因素，显示公司在医药领域的技术实力和发展潜 力。 2、公司经营状况有所改善，2026 年 1 月 30 日公布 2025 年报显示亏损小幅减少，归 ...

Core Viewpoint - The domestic first eye drop formulation containing recombinant human nerve growth factor, SMR001, is advancing towards market launch, with recent approval for its Phase III clinical trial aimed at treating moderate to severe dry eye disease [1][2]. Group 1: Product Development - ST Unimed's subsidiary, Shandong Yandu Biotechnology Co., has developed SMR001 eye drops, which are the first in China to use recombinant human nerve growth factor as an active ingredient [1][2]. - The product aims to repair damaged corneal nerves and promote epithelial regeneration, potentially offering a new treatment option for moderate to severe dry eye disease [1][2]. Group 2: Market Potential - The prevalence of dry eye disease globally ranges from 5% to 50%, with China reporting a rate of approximately 21% to 30%, indicating a significant public health issue [1]. - The incidence of dry eye among the 18-35 age group in China has reached 63%, a 400% increase over the past decade, driving growth in the pharmaceutical market [2]. - The Chinese ophthalmic drug market is projected to reach 44 billion yuan by 2025 and 108.4 billion yuan by 2030, with the dry eye drug segment expected to grow to 4.79 billion yuan in 2024, reflecting a compound annual growth rate of 16.17% from 2020 to 2024 [2]. Group 3: Clinical Trial Progress - SMR001 eye drops received a clinical trial notification on May 25, 2020, completed Phase I trials by February 26, 2022, and has shown effectiveness in treating moderate to severe dry eye disease in Phase II trials [3]. - The recent approval for the Phase III clinical trial marks a significant step in validating the efficacy and safety of SMR001 for patients with moderate to severe dry eye disease [3].